Second, and in contrast, cetuximab and EGFR-targeted therapy has long been an approved treatment protocol for RAS wild-type, metastatic colorectal cancer, and SHP2 inhibitors reliant on phospholipase C gamma 1 (PLCg1) exhibit anti-tumor effects in cancer cells resistant to cetuximab (113). Here, EGFR is linked to neoplasm.